<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662970</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.2, 09.07.2019</org_study_id>
    <nct_id>NCT04662970</nct_id>
  </id_info>
  <brief_title>Optimization of Cardiac Resynchronization Therapy by Non-Invasive Imaging of Cardiac Electrophysiology</brief_title>
  <acronym>NICE CRT</acronym>
  <official_title>Optimization of Cardiac Resynchronization Therapy by Non-Invasive Imaging of Cardiac Electrophysiology: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim is to analyze total left and right ventricular activation time in different&#xD;
      CRT device programming algorithms (SyncAV) measured by non-invasive electrophysiology&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient specific anatomic parameters taken from the cardiac magnetic resonance examination&#xD;
      will be the base for a semiautomatic model incorporating the conductivity of the heart, the&#xD;
      lungs, blood and the torso. For this reason, a software package (AMIRA Developer, TGS&#xD;
      Template Graphics Software, France) has been adapted to calculate a quasi static&#xD;
      approximation of Maxwell equations.&#xD;
&#xD;
      After fusion of the T1 CMR scan and the ECG electrodes a model-based bidomain FEM is used for&#xD;
      a step-wise measurement of the local activation times (resting potential: 290 mV; plateau: 0&#xD;
      mV; acceleration time: 3 ms) both Ende- and epicardially.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal (shortest) activation time of the right and left ventricular in heart failure patients after CRT implantation</measure>
    <time_frame>The measurements will be done at Day 1</time_frame>
    <description>The activation time will be measured in 16 different device programming settings</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Device programming</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>according to different settings from the SyncAV algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Device programming</intervention_name>
    <description>Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming</description>
    <arm_group_label>Device programming</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients after successful implantation of a CRT-D or CRT-P device in whom a cardiac&#xD;
             magnetic resonance examination is possible and the device is equipped with the SyncAV®&#xD;
             programming software&#xD;
&#xD;
          -  left bundle branch block before CRT implantation&#xD;
&#xD;
          -  PQ interval ≤ 250 ms before implantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  high-grade AV block&#xD;
&#xD;
          -  any contraindication concerning a safe CMR performance including claustrophobia&#xD;
&#xD;
          -  terminal heart failure (NYHA IV) or cardiac decompensation&#xD;
&#xD;
          -  life expectancy &lt; 1 year&#xD;
&#xD;
          -  women with child-bearing potential, pregnancy&#xD;
&#xD;
          -  drug abusus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Dichtl, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolfgang Dichtl, MD PhD</last_name>
    <phone>004351250481388</phone>
    <email>dichtl@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabian Barbieri, MD</last_name>
    <phone>004351250482546</phone>
    <email>fabian.barbieri@i-med.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Dichtl, MD PhD</last_name>
      <phone>004351250481388</phone>
      <email>dichtl@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Fabian Barbieri, MD</last_name>
      <phone>00435125048546</phone>
      <email>fabian.barbieri@i-med.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

